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Abstract
Heme Oxygenase-1 (HO-1) has been shown to play a pivotal role in pregnancy outcome and its ablation leads to
abnormal placentation, intrauterine fetal growth restriction (IUGR) and subsequent intrauterine fetal death. Carbon
monoxide (CO) has been found to mimic the protective effects of HO-1 activity, rescuing HO-1-deficient fetuses.
This gasotransmitter arises in biological systems during the oxidative catabolism of heme by HO. Here, we explored
the potential of CO in preventing IUGR and established the optimal doses and therapeutic time window in a
clinically relevant mouse model. We additionally investigated the pathways activated upon CO application in vivo.
We established 50 ppm as the best lowest dose of CO necessary to prevent growth restriction being the optimal
time frame during days 3 to 8 of mouse pregnancy. CO lead to higher fetal and placental weights and avoided
fetal death without showing any pathologic effects. CO breathing further suppressed inflammatory responses,
diminished placenta apoptosis and complement deposition and regulated placental angiogenesis. Our results
confirm the protective role of the HO-1/CO axis and point this gas as an emerging therapeutic possibility which is
worth to further explore.
Introduction
In mammals, most embryonic losses occur during early
pregnancy [1,], which represents a critical period of
gestation because of the major developmental events
that take place, including placentation and embryonic
organogenesis [3,4,]. Placentation comprises extensive
angiogenesis in maternal and placental tissues, accompa-
nied by a marked increase in uterine and umbilical
blood flows [6,7]. Reduced placental vascular develop-
ment and increased vascular resistance are associated
with early embryonic mortality [8,]. Factors influencing
placental vascular development and function have a dra-
matic impact on fetal growth and development, and
thereby on neonatal survival and growth [10,11]. We
have recently identified the enzyme heme oxygenase-1
(HO-1) as a pivotal factor in supporting placentation
[12]. The protective effects of HO-1 on placentation can
be mimicked by administering mice partially deficient in
HO-1 (Hmox1+/-) with carbon monoxide (CO, 12). Exo-
genous supply of CO at low concentrations can regulate
many physiological processes without apparent toxicity
and is able indeed to restore the immunoregulatory and
cytoprotective effects of HO-1 after its pharmacologi-
cally inhibition in a variety of pathologies [13-15]. This
gasotransmitter is an endogenous product of heme
degradation through HO-1. CO has been shown to
exert cytoprotective effects by reducing pro-inflamma-
tory mediators, preventing vascular constriction,
decreasing platelet aggregation and inhibiting apoptosis
[13] and was proposed to be a placenta vasodilator [16].
CO has been also implicated in the angiogenic response
associated with induction of HO-1 [14,15].
Having learned that HO-1 is crucial for placentation
and intrauterine fetal survival via CO, we aim here to
investigate the therapeutic potential of CO in avoiding
pregnancy complications. To do so we established the
optimal doses and time frame of treatment with CO via
inhalation in a clinically relevant model of intrauterine
growth restriction (IUGR). We analyzed the possible
toxic effects of the therapy as well as the pathways acti-
vated at throphoblast level after CO application.
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Materials and methods
Mice
CBA/J, DBA/2J and BALB/c mice were obtained from
Charles River, Sulzfeld, Germany, and maintained in our
animal facilities in Berlin and Magdeburg, Germany
with a 12 h light/dark cycle with water and food ad libi-
tum. Experimental procedures were approved by the
German authorities (LaGeSo Berlin 0062/03 and Land-
esverwaltungsamt Sachsen-Anhalt AZ: 2-868 University
of Magdeburg). We performed our experiments using
the well-established combination CBA/J x DBA/2J,
which has been recently described as a suitable IUGR
model [17]. Mating of CBA/J females with BALB/c
males served as a control combination as it represents a
normal pregnancy. Two months old CBA/J females were
mated with 2-4 months-old BALB/c or DBA/2J males,
checked twice a day for vaginal plugs and separated
from the males if pregnant. The day of the vaginal plug
was considered as day 0 of pregnancy. Animals were
treated with mixed air (20.9% O2, pharmaceutical com-
pressed air) or CO as indicated below.
CO exposure
Mice were placed in a 98-liter Plexiglas animal chamber
(A-Chamber, BioSpherix, NY, USA) and exposed to CO
(50 or 125 parts per million, ppm mixed with air) during
either days 3 to 5 or 3 to 8 of pregnancy as explained
elsewhere [12]. Control mice were maintained in a simi-
lar chamber without CO, only receiving the mixed air.
The gas flow into the Plexiglas chambers was main-
tained continuously at a rate of 12 liter/min. CO at a
concentration of 5% (50.000 ppm) in balanced air
(20.9% oxygen) was mixed with compressed air to
obtain a final concentration of 50 or 125 ppm before
being delivered into the exposure chamber. The com-
pressed air came from a 7 bar in house air-supply sys-
tem and the CO from a high-pressure bottle (Linde Gas
Therapeutics GmbH, Unterschleißheim, Germany). CO
concentration was controlled by varying the flow rate of
CO using a flowmeter (Q-Flow, Vögtlin Instruments,
Switzerland) before delivering to the chamber. Because
the flow rate (12 liter/min) is primarily determined by
the air flow, only the CO flow was changed to deliver
the final concentration to the exposure chamber. A CO
monitor (X-am 2000 Multi-gas Monitor, Dräger, Ger-
many) was used to measure CO levels in the chamber.
Gas samples were introduced to the monitor through a
port in the side of the chamber and were analyzed by
electrochemical detection (DrägerSensor XXS CO - 68
10 882, Dräger, Germany). Concentration levels were
measured periodically and there were no fluctuations in
the CO concentration after the chamber had equili-
brated (approximately 10 min). The chambers were
housed in a fume hood during the experiments and the
room was equipped with a CO alarm. In the chambers,
gas flowed at controlled rates to obtain the desired CO
exposure conditions.
Experimental settings: Animal groups
For analysing the effect of CO on pregnancy outcome in
mice known to develop IUGR, CBA/J females mated
with DBA/2J males (n = 8/ group) were treated with dif-
ferent CO doses (50 and 125 ppm) as follows:
a) 125 or 50 ppm of CO were applied during implan-
tation window (days 3-5 postcoitum, dpc)
b) 50 ppm of CO were applied during implantation
and early placenta development (3-8 dpc)
CBA/J animals previously mated with BALB/c males
(normal pregnancy) were treated with 50 ppm CO to
study the effect of this gas in normal pregnancies. This
was mainly due to discard toxic effects of CO in the
normal pregnancy combination.
Implantation rate as well as the percentage of fetal
death was analyzed at day 14 of pregnancy after sacrifi-
cing the animals by calculating the percentage of non-
viable implantations to the total number of implanta-
tions (viable + non-viable) multiplied by 100. Placentas
and fetuses were weighted. Tissue samples were
obtained for flow cytometry, real-time-PCR, histopathol-
ogy and immunohistochemistry studies.
In a second experiment, females of the IUGR combi-
nation (n = 8) were treated with 50 ppm of CO during
days 3-8 being the animals sacrificed directly after CO
exposure (day 8) to analyze the immediate effect of CO
application at trophoblast level.
Measurement of Carboxyhemoglobin (COHb)
Blood was taken from the heart of the anesthetized ani-
mal and COHb as well as total hemoglobin (tHb) were
analyzed by a blood gas analyzer (ABL 520, Radiometer,
Copenhagen).
Flow cytometry
Cells isolated from spleen, lymph nodes or decidua (18)
were incubated for 1 hour with 50 ng/ml phorbol 12-
myristate 13-acetate (PMA) and 1 μg/ml ionomycin at
37°C with 5% CO2 for stimulation of cytokine secretion.
To allow intracellular accumulation of secreted proteins
2 μM of monensin was added and incubated for further
3 hours. Cells were washed and incubated with antibo-
dies against surface markers for 10 min at 4°C in dark-
ness. For fixation, paraformaldehyde solution (PFA) at a
concentration of 1% (p/v) was used, and cells were incu-
bated overnight (ON) at 4°C. For detecting intracellular
proteins, cells were washed and antibodies diluted in
saponin 0.1% (p/v) were incubated for 20 min at 4°C in
darkness. After the incubation time, cells were washed
with saponin solution. The labelled cells were finally
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resuspended in FACS buffer and analyzed in a FACS
Calibur (Becton Dickinson) cytometer. The lymphocyte
population was gated based on size and granularity and
used for further analysis. When only analysing extracel-
lular markers, incubation with PMA, ionomycin and
monensin was avoided. Antibodies used included: FITC-
labelled anti-CD4; PE-labelled anti CD25, TNF-a, IFN-g
and IL-17; PE-Cy7-labelled anti CD3 (all purchased
from BD Biosciences, Heidelberg, Germany).
Immunohistochemistry (IHC)
Placenta samples were fixed in 96% ethanol and
embedded in paraffin as described by Saint-Marie (see
[19]). For detecting VEGF, paraffin samples were
dewaxed with xylol (2 × 20 min) followed by a series of
incubations in ethanol (100%, 95% and 75%, 10 min
each), with a final incubation of 5 min in distilled water.
The sections were washed with Tris buffered saline
solution (TBS, pH = 7.40) for 10 min and treated with
3% hydrogen peroxide in methanol for 30 min at room
temperature (RT) to block the endogenous peroxidase
activity. After washing, the tissues were exposed to 5%
BSA in TBS for 20 min at RT for protein blocking,
stained with the primary antibody (goat anti-VEGF,
Santa Cruz, San Diego, USA) diluted 1:100 in 5% BSA
in TBS and incubated ON at 4°C. The tissues were
washed and further stained with the secondary antibody
(rabbit anti-goat, Dako, Germany) diluted in 5% BSA in
TBS for 1 h at RT. After washing, the samples were
incubated for 30 min with an AB-Complex/HRP solu-
tion (Dako, Germany). Finally, they were developed with
AEC+ Substrate Chromogen (Dako), counterstained
with Hematoxylin and mounted. Negative controls were
obtained by replacing the first antibody with 5% BSA or
goat diluted serum. For complement staining, 8 μm
thick sections were cut, fixed and incubated with goat
anti-mouse C3 (Cappel) 1:200, diluted in 5% BSA in
TBS for 60 min at RT. As secondary antibody, we
employed rabbit anti-goat biotinylated 1:200 for 60 min
at RT. After washing, the samples were incubated for 30
min with an AB-Complex/HRP solution, developed with
AEC+ Substrate Chromogen, counterstained with
Hematoxylin and mounted.
TUNEL assay
Paraffin-embedded placenta sections were dewaxed and
hydrated as already described. This was followed by a
permeabilization of the samples with 0.1 M citrate buf-
fer. The detection of apoptotic cells was performed fol-
lowing manufacturers instructions using the in situ Cell
Death Detection Kit, POD (Roche Diagnostic Systems,
Mannheim, Germany) but changing the incubation tem-
perature to RT instead of 37°C. Amino-9-ethylcarbazole/
substrate chromogen (DakoCytomation, Eching,
Germany) and a counterstaining with Hemalaun (Roth,
Karlsruhe, Germany) was used for visualization of apop-
totic cells. Negative controls were performed by using
only the label solution. All sections were analyzed under
the light microscope by two independent observers
without knowledge of the samples. The numbers of
TUNEL+ cells per mm2 of placental tissue were evalu-
ated with a scaled eyepiece, pre-calibrated with a slide
micrometer.
Protein isolation and western blot analysis
Frozen placenta pieces were homogenized in lysis buffer
(1% NP-40, 0,1 mg/ml n-Dodecil beta maltoside, 10 mM
NAO3V, 1 M Tris pH 7.5, 5 m NaCl, 500 mM NaF, 500
mM EDTA pH 7,5, 100 mM PMSF) for 45 min. After
isolation, homogenates were centrifuged at 12.000 rpm
for 20 min at 4°C and the supernatant containing the
proteins was transferred to a fresh tube. Protein concen-
tration was assessed using the Pierce BCA Protein Assay
(Thermo Thermo Fisher Scientific, Bonn, Germany) as
indicated by the manufacturer. Protein samples were
kept at -80°C and while working with them, they were
always kept on ice. For Western Blot analysis, 20 μg of
protein (for Bag-1, sFlt-1 and sEng analysis) or 50 μg of
protein (for VEGF analysis) were transferred into a 8%
(sFlt-1), 10% (Bag-1 or sEng) or 15% (VEGF) polyacryla-
mide gel and a SDS-PAGE in denaturizing conditions
was performed at 100 V. After the electrophoresis pro-
teins were transferred into PVDF membranes in transfer
buffer containing 20% methanol (v/v), 0,19 M glycine
and 0.025 M Tris-base pH 8,3. For protein detection,
membranes were incubated with primary antibodies for
2 h with rabbit polyclonal antibody against Bag-1
(1:500), or overnight (ON) with goat polyclonal antibody
against VEGF (1:100), sFlt-1 (1:200) or sEng (1:200) all
from Santa Cruz, Biotechnology, San Diego, USA. After
three washing steps with TBST (TBS with 0.5% Tween)
for 5 min each, the membranes were then incubated
with an anti rabbit HRP-conjugated (Thermo Fisher
Scientific) or anti goat biotin-conjugated (Dako) anti-
body diluted 1:2000 for 1 h at RT and then with avidin-
horseradish peroxidase complex (ABC complex, Biozol).
GAPDH or b-Actin was used as loading control. The
chemiluminescence signal was generated by using lumi-
nol (A8511-5G, Sigma-Aldrich), 4-hydroxycinnamic acid
(p-coumaric acid; C9008-25G, Sigma Aldrich), and
hydrogen peroxide (Merck, Darmstadt, Germany). The
intensity of the bands was quantified by using the Gen-
eSnap® Software, Version 4.01c from Syngene.
RNA isolation, cDNA synthesis and Real-time RT- PCR
RNA extraction was performed using Trizol® Reagent
(Invitrogen, Darmstadt, Germany). Briefly, frozen pla-
centas (100 mg) were treated with 1 ml Trizol® and
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disaggregated using an Ultra-Turrax T25 homogenizer.
Isolation of RNA, cDNA synthesis and RT-PCR was
performed as described elsewhere [18]. For Bag-1 Bcl,
Bclxl, Bax, RT-PCR was performed using TaqMan tech-
nology. For amplifying VEGF, PGF, SDF-1a and HIF-
1a, RT-PCR was performed using SYBR green technol-
ogy (Applied Biosystems, Warrington, UK), both with
the i-Cyler (Biorad, Munich, Germany). b-Actin was
used as house keeping gene. The amount of mRNA was
calculated as 2-ΔCt in both cases. Primer sequences are
available upon request.
Results
50 ppm CO application during days 3-8 of pregnancy was
effective in preventing fetal loss while not provoking
deleterious effects in mothers or pups
The model chosen to explore the effect of CO application
is a relevant one for studying IUGR [17]. Additionally, it
has been shown that in this particular model, the HO-1
expression is diminished in placenta from mice of the
IUGR combination compared to the controls [20,21].
Application of 125 ppm CO during days 3-5 of pregnancy
slightly diminished the rate of fetal loss as compared to
air-treated controls (Figure 1a). Placentas from CO-trea-
ted animals were all normal; fetuses were not. In mater-
nal blood, carboxyhemoglobin (COHb) or total
hemoglobin (tHb) levels were not modified by this treat-
ment (Figure 1b and 1c). Fetal death was not character-
ized as in the controls by resorbed, hemorrhagic feto-
maternal units but by abnormalities in the fetuses
(smaller size, abnormal color, disintegrated tissue) as
representatively showed in Figure 1d and 1e. This sug-
gests that albeit having a rather positive effect on pla-
centa and partially protecting from fetal death, this
particular CO dose may be not the adequate one. Next,
we treated pregnant mothers with a lower CO concentra-
tion (50 ppm) during the same time period and observed
no undesired effects of the gas on the surviving fetuses.
CO at this time frame and concentration, however, did
not diminish the rate of fetal loss (Figure 1f). Neither
COHb nor tHb levels in maternal blood were modified
by this treatment (Figure 1g and 1h). We next tested
whether 50 ppm in an extended period of time, namely
during implantation and during early placentation (days
3-8) may be effective in preventing fetal loss We observed
that fetal loss was positively influenced by CO treatment,
it decreased from 30% in air treated controls to 0% in
mice receiving 50 ppm CO (Figure 2a), without any
apparent toxic effect on the fetuses. COHb and tHb
levels from maternal blood were not modified by this
treatment (Figure 2b and 2c). Interestingly, the applica-
tion of 50 ppm CO during implantation and placentation
significantly augmented the weight of fetuses (Figure 2d)
Figure 1 Effect of moderate (125 ppm) and low (50 ppm) CO
concentration during implantation window on murine
pregnancy outcome. (a) Pregnant mice treated with 125 ppm of
CO during implantation window (days 3-5 of pregnancy) show
sligthly diminished fetal loss rate compared to air-treated controls as
analyzed on day 14 of pregnancy (b) Maternal COHb and (c) tHb
levels were comparable among the groups. (d, e) Treatment with
125 ppm of CO provoked the pregnant mice to carry abnormal
fetuses (d, e). Exposure of pregnant females to 50 ppm of CO
during days 3-5 of pregnancy did not modify pregnancy outcome
when compared to air-treated controls (g). Neither COHb (h) nor
tHb levels (i) in maternal blood were modified by this treatment.
The data are shown as medians. *p < 0.05, as analyzed by the non-
parametric Mann-Whitney U-test between two groups.
Figure 2 CO treatment applied during embryo implantation
and early placentation positively influence pregnancy
outcome. (a) Inhalation of low amounts of CO (50 ppm) during
implantation and early placentation (days 3-8) completely prevented
fetal loss as analyzed on day 14 of pregnancy. COHb (b) and tHb (c)
levels in maternal blood were not modified by the treatment. 50
ppm CO applied during days 3-8 of pregnancy augmented the
weight of fetuses (d) and placentas (e). Sacrificing the animals
immediately after CO treatment (day 8 of pregnancy) revealed no
differences in the levels of COHb and tHb among the groups (f and
g). Data are shown as median. **p < 0.01, as analyzed by the non-
parametric Mann-Whitney U-test between two groups. e-f data are
shown as mean. ** < 0,01 as analyzed by unpaired t-test.
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and placentas (Figure 2e). Normal pregnant animals
(BALB/c-mated CBA/J females) which were exposed to
CO did not show any differences regarding pregnancy
outcome, COHb levels, placental/fetal weight or appear-
ance of the fetuses after the treatment as compared to
air-exposed animals (data not shown). Because the ani-
mals were sacrificed 6 days after the CO treatment and it
may be possible that a putative augmentation in the
COHb levels is not longer detectable at this time point,
we next applied CO at the same conditions (50 ppm dur-
ing days 3-8 of pregnancy) but sacrificed the animals
immediately after treatment. The COHb and tHb levels
at this time point were also comparable to the controls
(Figure 2f and 2g). Thus, this is another parameter indi-
cating that CO at this concentration is not toxic. Thus,
this dose of CO does not provoke any deleterious effect
in normally developing pregnancies, while having a posi-
tive effect on placental and fetal weight while it reduces
significantly the intrauterine fetal death.
Inhaled CO at 50 ppm during days 3-8 of pregnancy has
anti-inflammatory effects
We next asked whether the in vivo CO application pro-
voked any changes in the cytokine profile secreted by
lymphocytes at the periphery or at the fetal-maternal
interface. It is known e.g. that Th1 and Th17 cytokines
are associated with pregnancy loss (18, 22) while Th2
cytokines are known to support pregnancy (23). We
could not observe any changes in the secretion of TNF-
a among the groups. Immune cells from spleen and
decidua secreted less IFN-g in those pregnant mice pre-
viously exposed to CO as compared to the air-treated
controls (Figure 3d and 3e) as compared to animals
treated with mixed air. CO was also able to diminish
the secretion of IL-17 in cells from decidua, spleen and
iliac lymph nodes (Figure 3 g-i). Additionally, CO
diminished the percentage of CD4+CD69+ activated cells
while increasing the frequency of CD4+FoxP3+ regula-
tory T cells in iliac lymph nodes (data not shown)
These data suggest that the positive effect of CO on pla-
cental and fetal weight as well as on fetal survival is
associated with a shift of the immune response to a
non-inflammatory, protective one.
Inhaled CO diminished the apoptosis rate in placenta
while augmenting the levels of the cytoprotective
molecule Bag-1
We analyzed the effect of CO on apoptosis rate as well
on the expression of several molecules of the apoptosis
pathway. The analysis of apoptotic cells by TUNEL car-
ried out on samples from day 14 of pregnancy reveals
that the apoptosis rate is significantly down-regulated in
the CO-treated group compared with the air-treated
group (Figure 4a-c). We wondered whether exposure to
CO may diminish apoptosis by stimulating the expres-
sion of tissue-protective molecules, like Bag-1, Bcl-2 or
Bcl-xL in placental tissue. We found the anti-apoptotic
molecule Bag-1 to be significantly up-regulated after
treatment with CO when compared with the air-treated
group. This was true at protein as well as at mRNA
level (Figure 4d-4e). The mRNA levels of the other mea-
sured antiapoptotic/cytoprotective molecules were not
influenced by CO treatment (data not shown). Thus,
CO further supports the well being of the placenta by
inhibiting apoptosis and augmenting the levels of Bag-1.
Application of CO had a pro-angiogenic effect in the
placenta
Because of the known effect of CO on angiogenesis, we
next investigated whether the in vivo treatment with CO
had an effect on levels of molecules positively associated
with angiogenesis at trophoblast level. We concentrated
on the expression of vascular endothelial growth factor
(VEGF) that promotes the repair of injured vessels by
stimulating angiogenesis and re-establishing vascular
integrity [24]. CO inhalation significantly enhanced
VEGF protein and mRNA levels (Figure 5a-5b). To
identify the cells expressing VEGF, we next conducted
immunohistochemistry. We observed that, in line with
the Western Blot and PCR results, placentas from CO-
Figure 3 CO application diminished the levels of IFN-g+, IL-17+
but not TNF-a+ cells. The percentage of TNF-a+ cells in decidua
(a), spleen (b) and iliac lymph nodes (c) of pregnant mice was not
modified by treatment with 50 ppm CO. The percentage of IFN-g+
cells in decidua (d) and spleen (e) were significantly decreased after
50 ppm CO treatment as compared to animals which received
mixed air. No differences were found for the levels of these
molecules in lymph nodes (f). CO treatment lead to a significant
diminution in the percentage of IL17+ cells in decidua, spleen and
lymph nodes (g, h, i). Pregnant animals were treated either with
mixed air or 50 ppm CO during days (3-8 of pregnancy) and
sacrificed on day 8 of pregnancy. Percentage of cells positive for
TNF-a+, IFN-g+ or IL-17+ were analyzed by flow cytometry and
expressed as dot plots showing the median. Statistical significances
were analyzed by the non-parametric Mann-Whitney U-test
between two groups. *:p < 0.05 and **: p < 0.01.
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treated mice exhibited an intense staining of VEGF in
trophoblasts (Figure 5d), which was not the case for air-
treated controls (Figure 5c). The quantification of the
number of VEGF+ trophoblasts confirmed this (Figure
5e). We next analyzed whether CO treatment modifies
the levels of hypoxia-inducible factor (HIF)-1a, which is
a transcription factor regulating the expression of sev-
eral angiogenic factors and inducing angiogenesis [25].
HIF-1a is also a primary regulator of VEGF induction
in hypoxic conditions and recent in vitro studies
demonstrated that CO can stabilize HIF-1a [26]. In
comparison to air-treated females, HIF-1a mRNA levels
were upregulated in those mice who inhaled CO (Figure
5f). Recent data implied HO-1 derived CO as a critical
regulator of stroma cell-derived factor (SDF)-1 mediated
angiogenesis [27]. Real time RT-PCR revealed signifi-
cantly elevated levels of SDF-1 mRNA in placentas from
CO-treated animals (Figure 5g). We could also observe
a positive effect of the in vivo CO treatment in the ele-
vation of placenta growth factor (PGF, Figure 5h), which
promotes angiogenesis as well. Additionally, CO treat-
ment significantly diminished the levels of soluble VEGF
receptor, the fms-like tyrosinkinase (sFlt-1) as well as of
soluble endoglin (sEng) as it is shown in Figure 6a, b
and 6c, d respectively. Hence, CO has a pro-angiogenic
effect which may contribute to support a vital develop-
ment of placenta.
Application of CO provoked a diminution in the levels of
complement deposition
Because the adenoviral-mediated overexpression of HO-
1 increased decay accelerating factor (DAF) expression
Figure 4 CO treatment significantly diminished cell death in
placental tissue and up-regulated the expression of the anti-
apoptotic molecule Bag-1. (a) Analysis of DNA fragmentation by
TUNEL staining carried out in samples containing placental tissue
from day 14 of pregnancy revealed a significant diminution in the
number of apoptotic cells in the CO-treated group compared to air
treated group. Representative pictures show the abundant presence
of TUNEL positive cells in placental tissue from control animals (b)
or the almost absent TUNEL positive cells in placental tissue from
CO-treated animals (c). The bars represent 50 μm. (d-e) The
expression of the anti-apoptotic gen Bag-1 was up-regulated in
placental tissue from animals receiving CO treatment compared to
control animals at both protein (d) and mRNA (e) level.
Representative picture showing a western blot is included in (d).
Data are presented as median. Statistical significances were
evaluated by the non-parametric Mann-Whitney-U test. *:p < 0.05.
Figure 5 Carbon monoxide application augments the levels of
pro-angiogenic molecules in the placenta. Inhalation of 50 ppm
CO led to a significant augmentation in the expression of the pro-
angiogenic molecule VEGF in placenta samples at protein level (a)
as well as at mRNA level (b). This was also true for VEGF protein
levels as confirmed by immunohistochemistry, which clearly shows
an intense staining in trophoblast cells from animals treated with
CO (d) which was not the case for air treated control animals (c).
Quantification of the numbers of cells in each group revealed a
significant up-regulation of VEGF positive cells in placentas from
CO-treated mice (e). CO further induced an up-regulation in the
levels of reported pro-angiogenic molecules HIF-1 (f), SDF-1 (g) and
PGF (h) at mRNA level as compared to air-treated control animals.
Data are presented as median. Statistical significances were
evaluated by the non-parametric Mann-Whitney U-test between
two groups. *: p < 0.05 and **: p < 0.01 and ***: p < 0.001. Bars
represent 50 μm.
Figure 6 Carbon monoxide application diminishes the levels of
SFlt-1 and sEng in the placenta. Inhalation of 50 ppm CO led to a
significant diminution in the expression of the VEGF soluble
receptor sFlt-1 at protein level (a, b). CO treatment also diminished
the protein levels of sEng as analyzed by Western Blot (c, d). Data
are presented as single dots and medians. Statistical significances
were evaluated by the non-parametric Mann-Whitney U-test
between two groups. ***: p < 0.001.
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prevented C3 deposition and complement-mediated lysis
[28], we wondered whether the modulation of comple-
ment activation by CO may ameliorate placental vascu-
lar injury and their associated abnormal pregnancy
outcomes. We tested the intensity of C3 staining in pla-
centas from air or CO-treated mice and observed that
CO breathing significantly prevented C3 deposition as
observed in placentas from CO-treated mice compared
to placentas from mice that were exposed to mixed air
(Figure 7).
Discussion
One of the leading causes of perinatal morbidity and
mortality is intrauterine growth restriction (IUGR)
[29,30]. This has further serious consequences as predis-
position to lifelong increased risk of hypertension, cardi-
ovascular disorders, renal disease among others [31,32].
Thus, there is an urgent need for solutions to avoid or
reduce the occurrence of IUGR.
During human, rat and mouse pregnancies the expres-
sion of heme oxygenase-1 (HO-1) is highly induced at
trophoblast level [19,20,33,34] whereas miscarriages and
pre-eclampsia were showed to be associated with low
HO-1 expression in the placenta [19,35,36]. IUGR is
characterized as well by diminished HO-1 levels at the
fetal-maternal interface [37]. We have recently reported
that mice deficient in Hmox1 present aberrant placenta-
tion followed by a clear phenotype of IUGR and subse-
quent intrauterine fetal death [12]. This phenotype is
caused by the accumulation of free heme and can be
totally prevented by the inhalation of carbon monoxide
(CO), an important metabolite of the heme breakdown
by HO-1 [12]. Thus, HO-1 emerges as a key regulator
of placenta physiology and fetal development, while CO
overtakes the center of the scene. Having demonstrated
the ability of CO to prevent IUGR and fetal death
caused by insufficient HO-1 levels [12], we concentrated
on analyzing the therapeutic potential of CO in a clini-
cally relevant model of IUGR as in humans a relation-
ship between IUGR and low HO-1 activity has been
widely demonstrated [37].
Here, we show that the success and effectiveness of
the therapy are highly dependent on both the doses and
the time frame of CO application. While a relatively
high dose (125 ppm) during embryo implantation can
apparently prevent fetal loss, it presents undesired
effects on the fetuses. A lower doses (50 ppm) at the
same time frame (days 3-5 of pregnancy) is not toxic
but is not efficient in preventing fetal death. The same
low doses (50 ppm) applied longer, namely during
implantation and placentation (days 3-8 of pregnancy)
can effectively prevent fetal death while being not toxic.
We recently showed that the application of 50 ppm dur-
ing days 5-8 (placentation) also prevents fetal death
[12]. It is therefore tempting to speculate that the dose
and application period of CO is dependent on the con-
centration and/or activity of heme oxygenases in the
placenta. CO application to heterozygote Hmox1+/- mice
during days 3-8 can prevent fetal death and restore the
otherwise altered proportion of Hmox1+/+, Hmox1+/-
and Hmox1-/- progeny. This clearly works via normaliza-
tion of the placentation as we could observe in vivo [12].
In the present study, we observed a positive effect of CO
on placental and fetal weight in an animal model of
IUGR, which goes in line with the results obtained for
HO-1-deficient animals [12]. We discard toxicity related
to hypoxia after observing no changes in the levels
COHb. This was also true for animals that were sacri-
ficed immediately after treatment to analyze the
immediate effect of CO application. Normal pregnant
animals (Balb/c-mated CBA/J females) treated with low
CO did not show any differences regarding pregnancy
outcome. Normal pregnant controls did not show any
abnormalities after CO treatment as well. Accordingly,
rat pups whose mothers were chronically exposed to
low doses of CO during pregnancy showed no brain
damage [38].
Having confirmed that also in a clinically relevant
model CO can positively affect pregnancy and rescue
those fetuses in danger of developing IUGR and dying
intrauterine depending on the dose and time frame of
application, we wondered which pathways would be
activated after exposure to this gasotransmitter. We
found that CO breathing suppressed local inflammatory
Th1 and Th17 responses which are known to be asso-
ciated with pregnancy loss [18,22,23]. Thus, CO further
contributes to pregnancy success by shifting the
immune response to a non-inflammatory, protective
one. It is known that the protective effects of HO-1 are
Figure 7 CO treatment significantly diminished complement
(C3) deposition in the placenta. Analysis of C3 deposition after
CO or air treatment showed a positive effect of CO in avoiding C3
deposition as analyzed by immunohistochemistry (a-d) and analyzed
semiquantitatively (e). (a) and (c) show representative pictures from
each group at 40X while (b and d) show pictures taken with a 100X
objective. Data are presented as median. Statistical significances
were evaluated by the non-parametric Mann-Whitney-U test. *:p <
0.05.
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related with anti-apoptosis [14]. We found that this may
be also true for pregnancy, as HO-1-upregulation lead
to augmented levels of Bag-1 and less apoptotic cells in
the placenta [21,39]. Here, we confirmed that, as for
accounted for HO-1 augmentation, CO application
diminished the apoptosis rate in placentas and upregu-
lated the levels of Bag-1, known to be anti-apoptotic.
Treatment of placental villous explants with carbon
monoxide had a positive effect which relied on anti-
apoptosis [40]. CO seems therefore to be directly
implied in placental physiology and thus in placentation
and fetal growth by inhibiting apoptosis. We next con-
centrated on the effect of CO on angiogenesis, a process
which is essential for placentation. Besides, CO is
known to positively influence angiogenesis in several
models [41,42]. It has been widely demonstrated that
the induction of HO-1 activity positively contributes to
the regulation of the maternal vascular tone during
pregnancy [43]. CO was proposed to be involved in
angiogenesis by stimulating the production of vascular
endothelial growth factor (VEGF) in human microvessel
and vascular endothelial cells [44-46]. Moreover it was
shown that SDF-1 promotes angiogenesis in vitro, which
is mediated by HO-1 and CO [27]. Our results revealed
that in vivo CO treatment significantly upregulates both
VEGF and SDF-1 expression in placenta. Placenta
growth factor (PGF) was proposed to be involved in
angiogenesis and is known to be diminished in cases of
IUGR in humans [47,48]. We found here that the treat-
ment of animals with IUGR not only rescued fetuses
from death and augmented their weight but also aug-
mented the levels of PGF in placenta. This may indicate
PGF as one of the placental targets of CO, whose aug-
mentation contribute to the well-being of the placenta
and thereby to fetal survival. The idea of CO contribut-
ing positively to angiogenesis in the placenta is further
supported by the data we obtained when analyzing sFlt-
1 and sEng. It was already known that HO-1 and CO
inhibit soluble Flt-1 [36]. Girardi and colleagues found
elevated sFlt-1 levels in this particular mouse model
[49], which we found to be inhibited after CO breathing.
Similarly, the application of CO resulted in diminished
sEng. This clearly confirms the positive role of CO in
angiogenesis.
Placentation and embryonic development occurs pre-
dominantly in a hypoxic environment [50,51], being
HIF-1a of crucial importance in this process [52]. HIF-
1a was proposed to regulate HO-1 expression after
myocardial injury [53], and CO was reported to regulate
HIF-1a, suggesting a feed-back regulatory loop [26]. We
were able to confirm an upregulation in the levels of
HIF-1a mRNA in placenta from mice which were trea-
ted with CO. It is therefore tempting to speculate
that transient diminished O2 levels, necessary for
implantation [50] up-regulates HIF-1a locally which will
in turn induce the expression of cytoprotective genes to
avoid tissue damage at this particular time point and to
protect the embryo against oxidative stress. Tissue cyto-
protection is of particular importance in the placenta as
ensures the survival of the tissue and thereby determines
the adequate fetal support. The CBA/J x DBA/2J model
is longer known to be dependent on complement activa-
tion [49]. We observed that CO application conferred
protection against complement deposition as we ana-
lyzed by measuring C3 in the placenta. The same had
been previously observed for adenoviral-mediated HO-1
overexpression [28]. Complement modulation may
explain the positive effects of the gas in terms of vascu-
lar injuries as we observed that CO application normal-
ized placenta histology and restored pregnancy [12].
In conclusion, we have confirmed the positive effects
of CO on pregnancy outcome in an animal model of
IUGR which is clinically relevant. We show that the
effectiveness of CO-gas therapy depends on the careful
selection of the dose and time frame to be applied. This
is of extreme importance for the putative design of clini-
cal trials. We show that the positive effects of CO on
pregnancy, highlighted by prevention of fetal death and
increased fetal weight, are associated with an anti-
inflammatory local immune response, with tissue pro-
tection, anti-apoptosis and pro-angiogenesis.
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